Written by Clark on November 25, 2024 — Medically Reviewed by Clark
If you’ve been exploring weight loss options, you might have come across two newer treatments: ZepBound and Wegovy. These two drugs are both aimed at weight control, although they do so in somewhat different ways.
Today weight problems and diseases associated with it are rather widespread, therefore, information on these options become useful when determining which of them is more suitable for a person.
Here we will reveal such issues as comparison between ZepBound and Wegovy, the way of taking the medications, possible side effects, and tips to choose the best drug.
Overview of Zepbound and Wegovy
Active moiety in Zepbound is Tirzepatide, it interacts with the GLP-1 and GIP receptors to stimulate them for regulating food intake and hunger.
Zepbound injection was licensed by the Food and Drug Administration in managing obesity particularly in chronic patients. It is described as obese those who have BMI 30 kg/m2 and even over or overweight for those with BMI 27 kg/m2 and above and have one or more diseases associated with obesity such as hypertension, hyperglycemia and hypercholesteremia.
Semaglutide is the active substance of Wegovy, and the class of the medicine is GLP RA – glucagon peptide receptor agonist. They also stabilise blood glucose levels; reduce weight as insulin hormone is promoted while glucagon is restricted; delay the stomach’s emptying ability and overeat.
NICE has certified it as a substitute for obesity related problem in obese adult patients with BMI index of 35 and above.
How Do They Work?
Both medications are used to promote weight loss, but the way they achieve results can differ slightly.
ZepBound’s Mechanism
Zepbound belongs to the class of GIP and GLP agonist receptors since it targets both types of these receptors. The incretin, GIP is anticipated to interact with GLP-1 additively. These receptors are important in regulation of blood glucose and for appetite. Zepbound enhances insulin secretion from pancreas, suppresses glucagon level, enhances glycemic control, delays gastric emptying and controls satiety.
Wegovy’s Mechanism
It mimics an FDA-approved hormone called GLP-1 which sends signals to your brain that you’re full hence eating less. Many people use Wegovy through injections, which are given once a week and the slow release ensures that there’s only a small amount of fat in your system, making it easier to control your weight in the long run.
Effectiveness: How Much Weight Can You Lose?
Thus, both ZepBound and Wegovy are known for the advancement of substantial weight reduction, although preliminary outcome depends on individual factors, including diet, way of life, and initial weight.
ZepBound Results
In a 72 weeks large scale clinical trial, the patients on the maximum dose of the Zepbound tablets 15 mg, body weight was reduced on average to about 20 percent or more of the baseline body weight. Furthermore, sixty percent of participants in this group were able to indicate they lost at least twenty percent of their body weight.
Wegovy Results
In the course of 68 weeks, the patients who used Wegovy at a maintenance dose of 2.4 mg per day lost approximately 15 percent of their initial body weight on average. Less than 50% of the patients from the Wegovy group shed at least 5% of body weight as per the trial but more than half of these influential inhabitants lost potentially at least 15% of their body weight.
Side Effects: What Should You Expect?
As with any medication, side effects are a possibility with both ZepBound and Wegovy. Here’s a rundown of what you might experience with each.
For Zepbound, the once-weekly starting dosage is 2.5 mg for 4 weeks. After that, the dosage is increased to 5 mg once weekly. Some people may continue the 5 mg dose long term. If required the dose can be escalated after four weeks by a further 5 milligrams to 10 or 15 milligrams weekly.
Wegovy injection is administered subcutaneously using a pen injector. It begins at a dose of 0.25 mg/week in the first 4 weeks, then the subject raises the dose every 4 weeks up to a maintenance dose of 2.4 mg/week.
Costs and Accessibility
One has to sometimes look at the expense of a certain treatment since newer drugs might be considerably expensive.
ZepBound Pricing
With a manufacturer copay card you may have to pay as little as $25 for Zepbound if your commercial insurance covers the medication. However if this is not part of the plan, you can purchase Zepbound for $650 for a 30 day pack.
Wegovy Pricing
Applying for the Wegovy copay card means it can be free of charge if you have insurance or it can be $ 650 if you don’t have insurance or if you take Wegovy on your own.
Wegovy and Zepbound may be beneficial for different health issues
Studies have been done with Wegovy and Zepbound in other indications apart from obesity and cardiovascular disease. The result is affirmative, so such treatments have beneficial prospects and may be applied to other health illnesses in future. Here your health history might determine which of them should be taken as the most appropriate one for you.
Wegovy has been demonstrated to have clinical effectiveness in some selected patients with heart failure. Recently it has been observed with some kidney-related benefits in patients with heart disease.
There proves that Zepbound can help patients with moderate to severe OSA; obstructive sleep apnea. It may be approved for this usage before the end of the year 2024. It has also been tried in patients with heart failure or those who had MASH or with chronic kidney disease.
Wegovy is approved for usage in teens, and Zepbound is exclusively licensed for adults
Wegovy is one of the two drugs within its class that is approved for use in adults and in adolescents of twelve years of age and above. The other option that has been approved is Saxenda (Liraglutide). Although Zepbound is under consideration for application to adolescents it can only be given to adults.
Can you take Zepbound and Wegovy together?
No. As per the information it is not recommended to use both Zepbound and Wegovy. Often one is given the option to choose between the two and none of the two can be taken at the same time.
However if the recommended dose of the drug does not help in improving the condition then one should consult a doctor. In some cases maybe adjust or increase it or transfer you to another medicine depending on the situation.
Can you switch from Wegovy to Zepbound?
Yes. If you require some further intervention to address your weight, you can move from Wegovy to Zepbound.
In this case your doctor may suggest that you start taking a smaller amount of Zepbound and slowly build up. This just gives the body a chance to adjust to Zepbound and come to a realization of the right amount to administer depending on the kind of situation at hand.
Final Thoughts
ZepBound and Wegovy — it is not always easy to determine which of those is preferable, although understanding the pros and /or cons of each will help. Normally both drugs offer a route through which one can lose weight, but they differ in their abilities, side effects, and costs.
While Wegovy is mainly used in the first place in both adults and children at least 12 years of age, and Zepbound is only used in the adult population. Although the use of this brand may afford some measure of shedding more weight than Zepbound, this over-weight drug has been known to take care of cardiovascular disease in some people especially those with heart problems.
Last but not the least your doctor will tell you whether which treatment is good for you. Like with the weight loss thing, there is no miracle here, people are different, though once you get proper tools, trainer, and mindset it would not be difficult to reach the set goals. Proper communication can point one in the right direction towards improved health, and happiness.
Join over 2500 Subscribers to Our Weekly Newsletter
Our newsletter has tips, guides & resources that are all about your health and weight loss.
Min, T., & Bain, S. C. (2021). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Therapy, 12(1), 143-157.
Iacobucci, G. (2023). Appetite suppressant semaglutide is to be made available to treat obesity in England.
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., … & Kruse, T. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of medicinal chemistry, 58(18), 7370-7380.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., … & Petrie, M. C. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 389(12), 1069-1084.
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., … & Lincoff, A. M. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine, 1-9.
Woodard, K., Louque, L., & Hsia, D. S. (2020). Medications for the treatment of obesity in adolescents. Therapeutic Advances in Endocrinology and Metabolism, 11, 2042018820918789.